Vesicle

Capricor Announces Joint Publication with the US Army Institute of Surgical Research for Cardiosphere-Derived Exosomes as a Potential Therapeutic for Shock

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Medical emergencies, Acute pain, Traumatology, Vesicles, Cells, Extracellular vesicle, Vesicle, Major trauma, Coagulopathy, Injury, Shock

LOS ANGELES, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor” or “the Company”) (NASDAQ: CAPR), a biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating and preventing a broad spectrum of diseases, announced today the publication, of a manuscript, which shows that cardiosphere-derived exosomes (CDC-EVs) can attenuate kidney damage and promote new blood vessel formation in a preclinical model of acute trauma, both of which are important factors in post-shock recovery. The publication titled, “Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic” was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).

Key Points: 
  • The publication titled, Extracellular vesicles derived from cardiosphere-derived cells as a potential antishock therapeutic was published in the international peer-reviewed journal, The Journal of Trauma and Acute Care Surgery in collaboration with researchers at the United States Army Institute of Surgical Research (USAISR).
  • The military continues to look for therapeutics that can be delivered in the field to stabilize wounded warriors.
  • While cell therapy held promise in that arena, a lyophilized product that does not require ultra-cold storage is preferable.
  • The goal of the study was to determine the therapeutic potential of CDC-EVs in a rat model of acute traumatic coagulopathy induced by polytrauma and hemorrhagic shock.

Pacira Announces FDA Approval of Enhanced EXPAREL Manufacturing Process

Retrieved on: 
Monday, August 2, 2021
Branches of biology, Membrane biology, Local anesthetics, Drugs, Pharmacology, Acetanilides, Bupivacaine, Piperidines, Liposome, Approved Drug Products with Therapeutic Equivalence Evaluations, Vesicle

PARSIPPANY, N.J., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has approved the company’s enhanced manufacturing process for EXPAREL® (bupivacaine liposome injectable suspension) which is housed at a custom facility in Swindon, England under a partnership with Thermo Fisher Scientific Pharma Services. The company expects to start selling commercial product manufactured in this 200-liter suite later this year.

Key Points: 
  • This FDA approval underscores the quality assurance of our enhanced manufacturing process, which is essential as we scale the production of EXPAREL, said Dave Stack, chairman and chief executive officer of Pacira BioSciences.
  • The patent, Manufacturing of Bupivacaine Multivesicular Liposomes, claims composition of EXPAREL prepared by the improved manufacturing process and has an expiration date of January 22, 2041.Pacira submitted this patent for listing in the FDAs Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) in July 2021.
  • The companys long-acting local analgesic, EXPAREL (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012.
  • EXPAREL represents the first and only multivesicular liposome local anesthetic that can be utilized in the peri- or postsurgical setting.

Keystone Bio Advances a More Complete Explanation of Porphyromonas Gingivalis Toxic Virulence Factors as Major Driver of Sporadic Alzheimer’s and Chronic Inflammation

Retrieved on: 
Thursday, July 29, 2021
Biotechnology, Health, Consumer, Other Health, Pharmaceutical, Other Science, Mental health, Research, Managed care, General Health, Hospitals, Science, Dental, Seniors, Branches of biology, Medical specialties, Microbiology, Membrane biology, Bacterial vaginosis, Bacteroidetes, Porphyromonas gingivalis, Reproductive system, Sexual health, Biofilm, Virulence, Vesicle

View the full release here: https://www.businesswire.com/news/home/20210729006009/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210729006009/en/
    Using KB proprietary methods, KB has identified and eliminates a primary driver of our most deadly diseases, Porphyromonas gingivalis and all of its unique virulence factors.
  • A larger HagA Domain virulence factor is found in many AD and some aged matched control brain tissues.
  • Porphyromonas gingivalis Outer Membrane Vesicles as the major drivers of and source for the toxic insult and iron accumulation/deposition in Alzheimers Disease.
  • Porphyromonas gingivalis (Pg) is a primary oral pathogen in the widespread biofilm-induced chronic multi-systems inflammatory disease(s) including Alzheimers disease (AD).

Kanazawa University research: Regulators for extracellular vesicle production

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Biology, Cell biology, Organelles, Vesicles, Membrane biology, Vesicle, Extracellular vesicle, Secretion

KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.

Key Points: 
  • KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.
  • For the development of therapies, regulators that can inhibit the secretion of specific EVs, without severe side effects, are therefore needed.
  • By screening a large set of biomolecular compounds, Rikinari Hanayama from Kanazawa University and colleagues have now identified 4 potential regulators (1 inhibitor and 3 activators) for EV secretion for a variety of cells.
  • Rikinari Hanayama from Kanazawa University and colleagues have now screened more than 1500 biochemical compounds for their use as regulators of EV secretion either inhibiting or activating the process.

Kanazawa University research: Regulators for extracellular vesicle production

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Biology, Cell biology, Organelles, Vesicles, Membrane biology, Vesicle, Extracellular vesicle, Secretion

KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.

Key Points: 
  • KANAZAWA, Japan, July 13, 2021 /PRNewswire/ -- Researchers at Kanazawa University describe in Scientific Reports the identification of small compounds that can regulate the cellular production of extracellular vesicles nanocontainers transporting biomolecules between cells.
  • For the development of therapies, regulators that can inhibit the secretion of specific EVs, without severe side effects, are therefore needed.
  • By screening a large set of biomolecular compounds, Rikinari Hanayama from Kanazawa University and colleagues have now identified 4 potential regulators (1 inhibitor and 3 activators) for EV secretion for a variety of cells.
  • Rikinari Hanayama from Kanazawa University and colleagues have now screened more than 1500 biochemical compounds for their use as regulators of EV secretion either inhibiting or activating the process.

Exopharm (EX1): Initiation - All the parts for drug delivery development

Retrieved on: 
Monday, May 31, 2021
Branches of biology, Vesicles, Cell biology, Cells, Extracellular vesicle, Vesicle, EV, Exosome, Draft:Exopharm

We are initiating research on Exopharm, a company focused on providing solutions for the development of targeted therapeutics using extracellular vesicles (EVs).

Key Points: 
  • We are initiating research on Exopharm, a company focused on providing solutions for the development of targeted therapeutics using extracellular vesicles (EVs).
  • Its goal is to out-license this platform to one or more major pharmaceutical partners for the development of EV-based drugs.
  • EVs are small packets of plasma membrane that bud from a range of different cell types.
  • They were initially studied as therapeutics in their own right (ie nave EVs), but are also of great interest in drug delivery (engineered EVs).

Organicell Signs an Exclusive Distribution Agreement with Apex Services in Pakistan

Retrieved on: 
Wednesday, May 19, 2021
Research, Medical devices, Infectious diseases, Hospitals, FDA, Clinical trials, Stem cells, Biotechnology, Health, Science, Branches of biology, Biology, Cytokines, Cytokine, Immunology, Vesicle, Chemokine

This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues.

Key Points: 
  • This product contains over 300 growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from perinatal tissues.
  • Based in South Florida, the company was founded in 2008 by Albert Mitrani, Chief Executive Officer and Dr. Mari Mitrani, Chief Scientific Officer.
  • Specific information included in this press release may change over time and may or may not be accurate after the date of the release.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210519005143/en/\n'

Vesigen Therapeutics Presents Data on Recent Advances to its Engineered ARMMs Therapeutic Delivery Platform at ISEV 2021

Retrieved on: 
Tuesday, May 18, 2021
Branches of biology, Biology, Vesicles, Cell biology, Membrane biology, Medical diagnosis, Microvesicles, Nanotechnology, Vesicle, Extracellular vesicle, International Society for Extracellular Vesicles

b'CAMBRIDGE, Mass., May 18, 2021 /PRNewswire/ -- Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated delivery platform, today announced new data supporting the therapeutic potential of ARRDC1 Mediated Microvesicles (ARMMs) as vehicles for intracellular delivery of macromolecules.

Key Points: 
  • b'CAMBRIDGE, Mass., May 18, 2021 /PRNewswire/ -- Vesigen Therapeutics, Inc., a biotechnology company pioneering development of a novel extracellular vesicle-mediated delivery platform, today announced new data supporting the therapeutic potential of ARRDC1 Mediated Microvesicles (ARMMs) as vehicles for intracellular delivery of macromolecules.
  • Data will be shared in two virtual poster presentations at the 2021 International Society for Extracellular Vesicles (ISEV) Annual Meeting occurring May 18-21.
  • The presentations will highlight ARMMs payloading, purification and characterization, including demonstration of cellular uptake and intracellular cargo activity.
  • Vesigen will advance the ARMMs platform to develop innovative medicines for patients through an exclusive license agreement with Harvard University.\n'

Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-inflammatory Product Candidate EDP2939 at the American Association of Immunologists Meeting

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Vesicles, Cell biology, Drug discovery, Pharmaceutical industry, Cells, Extracellular vesicle, EV, Preclinical development, Vesicle

b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today presented preclinical data for its extracellular vesicle (EV) product candidate, EDP2939, for the treatment of inflammatory diseases, at Virtual IMMUNOLOGY2021, the 104th Annual Meeting of the American Association of Immunologists (AAI).

Key Points: 
  • b'CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today presented preclinical data for its extracellular vesicle (EV) product candidate, EDP2939, for the treatment of inflammatory diseases, at Virtual IMMUNOLOGY2021, the 104th Annual Meeting of the American Association of Immunologists (AAI).
  • \xe2\x80\x9cOur research and development teams continue to explore ways to optimize our product candidates through new forms and formulations, including our preclinical work with oral EVs.
  • We are pleased to share new data for our first anti-inflammatory EV product candidate, EDP2939, which demonstrated potent systemic anti-inflammatory activity after oral administration in mouse models.
  • These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.\n'

Yumanity Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Biology, Membrane biology, Organelles, Cell biology, Cell communication, Cell signaling, Systems biology, Vesicle, Biological membrane

These classes of lipid molecules regulate multiple diverse cellular properties and processes, including membrane structure and function, vesicle and organelle trafficking, intracellular signaling and inflammation.

Key Points: 
  • These classes of lipid molecules regulate multiple diverse cellular properties and processes, including membrane structure and function, vesicle and organelle trafficking, intracellular signaling and inflammation.
  • Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements.
  • Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval.
  • Yumanity explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.\n'